WO2007100722A3 - Methods to identify factors associated with muscle growth and uses thereof - Google Patents

Methods to identify factors associated with muscle growth and uses thereof Download PDF

Info

Publication number
WO2007100722A3
WO2007100722A3 PCT/US2007/004835 US2007004835W WO2007100722A3 WO 2007100722 A3 WO2007100722 A3 WO 2007100722A3 US 2007004835 W US2007004835 W US 2007004835W WO 2007100722 A3 WO2007100722 A3 WO 2007100722A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
factors associated
muscle growth
identify factors
identify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004835
Other languages
French (fr)
Other versions
WO2007100722A2 (en
Inventor
Kenneth Walsh
Noriyuki Ouchi
Yasuhiro Izumiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Priority to US12/281,115 priority Critical patent/US20110191871A1/en
Priority to AU2007221177A priority patent/AU2007221177A1/en
Priority to CA002644057A priority patent/CA2644057A1/en
Priority to EP07751587A priority patent/EP1996216A2/en
Publication of WO2007100722A2 publication Critical patent/WO2007100722A2/en
Anticipated expiration legal-status Critical
Publication of WO2007100722A3 publication Critical patent/WO2007100722A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

The present invention relates to methods to identify factors associated with muscle growth, angiogenesis, obesity, insulin sensitivity body weight, fat mass, muscle mass and cardiovascular ftinction. In particular, the methods of the present invention relates to assays to identify such factors using a transgenic animal model and/or a cell-based assay.
PCT/US2007/004835 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof Ceased WO2007100722A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/281,115 US20110191871A1 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof
AU2007221177A AU2007221177A1 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof
CA002644057A CA2644057A1 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof
EP07751587A EP1996216A2 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77765406P 2006-02-28 2006-02-28
US60/777,654 2006-02-28

Publications (2)

Publication Number Publication Date
WO2007100722A2 WO2007100722A2 (en) 2007-09-07
WO2007100722A3 true WO2007100722A3 (en) 2008-12-18

Family

ID=38459584

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/004793 Ceased WO2007100695A2 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof
PCT/US2007/004835 Ceased WO2007100722A2 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004793 Ceased WO2007100695A2 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof

Country Status (7)

Country Link
US (2) US20110191871A1 (en)
EP (2) EP1996215A2 (en)
JP (1) JP2009528355A (en)
KR (1) KR20080108487A (en)
AU (2) AU2007221245A1 (en)
CA (2) CA2644057A1 (en)
WO (2) WO2007100695A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2007041643A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
MX2011013903A (en) 2009-06-17 2012-05-08 Amgen Inc Chimeric fgf19 polypeptides and uses thereof.
EP2679234A3 (en) 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
RU2631597C2 (en) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Compositions and methods for metabolic pathway modulation
KR101330448B1 (en) * 2011-09-06 2013-11-15 고려대학교 산학협력단 Method for regulation of metabolic homeostasis, stress resistance, and lifespan by the endogenous siRNA(endo-siRNA) pathway
US20140335108A1 (en) * 2011-12-12 2014-11-13 Trustees Of Boston University Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases
JP2015502378A (en) * 2011-12-19 2015-01-22 ヤンセン・アールアンドデイ・アイルランド HIV membrane fusion inhibitor
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CN102807993B (en) * 2012-08-31 2014-04-09 西北农林科技大学 Skeletal muscle specific miRNA expression vector and reconstitution cell of target Myostatin gene
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
CN105228627B (en) 2013-03-15 2018-07-13 纽斯尔特科学公司 Leucine and niacin reduce lipid level
ES2782380T5 (en) 2013-10-30 2023-05-08 Univ Missouri Scalable Skeletal Muscle Lineage Culture and Specification Method
KR20160119863A (en) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. Compositions and methods for the reduction or prevention of hepatic steatosis
FR3021318B1 (en) * 2014-05-20 2017-04-28 Inst Biophytis 20-HYDROXYECDYSONE-DERIVED PRODUCTS AND THEIR USE IN THE PREPARATION OF MEDICAMENTS
EP3108893A1 (en) 2015-06-25 2016-12-28 Universite Claude Bernard - Lyon 1 Novel therapeutic use of fgf19
WO2017040287A1 (en) 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases
AU2016343978A1 (en) * 2015-10-29 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
WO2018208628A1 (en) 2017-05-06 2018-11-15 Memphis Meats, Inc. Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
WO2019014652A1 (en) 2017-07-13 2019-01-17 Memphis Meats, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
US10869465B2 (en) * 2017-08-10 2020-12-22 Osaka University Transgenic mouse model of retinal vascular disease, method of making, and method of using
WO2019060702A1 (en) * 2017-09-22 2019-03-28 Wayne State University Systems and methods to detect stress leading to miscarriage risk
US20240382513A1 (en) * 2021-07-09 2024-11-21 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
CN113509471B (en) * 2021-07-19 2023-06-13 中国药科大学 Application of AKT2 inhibitor in preparation of medicine for treating myocardial injury induced by doxorubicin
CN114213518B (en) * 2021-12-27 2023-04-18 北京大学 Tmem52 protein for regulating glycolipid metabolism, coding gene, sgRNA and application thereof
WO2023240152A1 (en) 2022-06-07 2023-12-14 Upside Foods, Inc. Engineering cell lines capable of proliferation in growth factor free media formulations
CN116554294B (en) * 2023-04-27 2024-03-15 北京大学 Tmem52 protein fragments, coding genes, recombinant vectors, recombinant microorganisms and their applications
CN116784275B (en) * 2023-08-11 2025-06-27 成都药康生物科技有限公司 Construction method and application of animal model of hepatic fibrosis or nonalcoholic steatohepatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005782A1 (en) * 1996-08-02 1998-02-12 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
CA2335391A1 (en) * 1998-10-02 2000-04-13 Kenneth Walsh Akt compositions for enhancing survival of cells
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
EP1395610A2 (en) * 2001-06-11 2004-03-10 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
US20030144204A1 (en) * 2001-12-19 2003-07-31 Baylor College Of Medicine Akt-based inducible survival switch
US7314911B2 (en) * 2004-08-17 2008-01-01 Board Of Regents, The University Of Texas System Prostate hyperplasia therapy
AU2005301988A1 (en) * 2004-11-08 2006-05-11 University Of Rochester Transgenic non-human animal models of ischemia-reperfusion injury and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHO H. ET AL.: "Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)", SCIENCE, vol. 292, no. 5522, June 2001 (2001-06-01), pages 1728 - 1731, XP002974608 *
SCHIEKOFER S. ET AL.: "Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure", PHYSIOL. GENOMICS, vol. 27, no. 2, October 2006 (2006-10-01), pages 156 - 170, XP002516471 *
SHIOJIMA I.: "Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure", J. CLIN. INVEST., vol. 115, no. 8, August 2005 (2005-08-01), pages 2108 - 2118, XP008130970 *
SHIOJIMA I.: "Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway", GENES DEV., vol. 20, no. 24, December 2006 (2006-12-01), pages 3347 - 3365, XP008130969 *

Also Published As

Publication number Publication date
WO2007100722A2 (en) 2007-09-07
EP1996216A2 (en) 2008-12-03
EP1996215A2 (en) 2008-12-03
US20110191871A1 (en) 2011-08-04
AU2007221245A1 (en) 2007-09-07
JP2009528355A (en) 2009-08-06
AU2007221177A1 (en) 2007-09-07
CA2644057A1 (en) 2007-09-07
WO2007100695A9 (en) 2008-12-31
US20090142336A1 (en) 2009-06-04
CA2644046A1 (en) 2007-09-07
WO2007100695A3 (en) 2008-08-21
WO2007100695A2 (en) 2007-09-07
KR20080108487A (en) 2008-12-15

Similar Documents

Publication Publication Date Title
WO2007100722A3 (en) Methods to identify factors associated with muscle growth and uses thereof
USD611372S1 (en) Analyte test meter
WO2007136267A3 (en) Set of plastic eating and/or drinking aids
WO2008067470A3 (en) Exercise kit for personal floatation device
EP2066277A4 (en) Toilet training using sensor and associated articles
EP1828953A4 (en) RIBOCOMMUTATEURS, STRUCTURE OF RIBOCOMMUTATE COMPOUNDS, AND METHODS AND COMPOSITIONS USED WITH RIBOCOMMUTATEURS
WO2006026367A3 (en) Garment with a venting structure
WO2009037548A3 (en) Variable hardness hand grip
WO2007087139A3 (en) MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR
WO2006047495A3 (en) Methods and materials for conferring resistance to pests and pathogens of plants
WO2008067205A3 (en) Food and beverage emulsifiers
MY160361A (en) Nutritional composition with anti-regurgitation properties
TW200628190A (en) Air resistance exercise device and method
WO2008128766A3 (en) Beverage composition
WO2007080621A8 (en) Luminescent transgenic non human animals, progeny, cell derivatives and uses thereof
EP1940518A4 (en) Milk derived composition and use to enhance muscle mass or muscle strength
EP1733179A4 (en) Drive-by-wire assembly with strain gauge
WO2007076145A3 (en) Golf swing training device
WO2011015851A3 (en) Self-weighing luggage
CA2657756C (en) Dry food to reduce dogs' appetites
CN201580715U (en) Bucket
WO2008049089A3 (en) Methods of determining potency of chemically-synthesized oligonucleotides
WO2009009767A3 (en) New bacillus thuringiensis toxin
WO2006131326A3 (en) Novel use of (-)-epigallocatechin gallate
Hayden Introduction to

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007221177

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12281115

Country of ref document: US

Ref document number: 2644057

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007221177

Country of ref document: AU

Date of ref document: 20070223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007751587

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07751587

Country of ref document: EP

Kind code of ref document: A2